Floatz logo

ZIDOVUDINE

Epstein Barr Virus Associated Non Hodgkin's Lymphoma

University of MiamiSmall moleculePhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

8 Active assets in the Epstein Barr Virus Associated Non Hodgkin's Lymphoma cohort.

Asset / SponsorPhaseRating
Tabelecleucel
Pierre Fabre Medicament
Phase 3BB
Valganciclovir
Viracta Therapeutics, Inc.
Phase 2B
Hydroxyurea
University of Miami
Phase 2CCC
Arginine Butyrate
HemaQuest Pharmaceuticals Inc.
Phase 2CCC
Ganciclovir
HemaQuest Pharmaceuticals Inc.
Phase 2CCC

View all 17 →

Same molecule, other indications

ZIDOVUDINE is also rated in:

HIV infectious diseaseDormant
BBB
Indicative ·
77 / 100
View asset →
lipodystrophyDormant
BBB
Indicative ·
76 / 100
View asset →
cardiovascular disorderDormant
BB
Indicative ·
70 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →